Evaluation of the effect of vincristine on platelet count in dogs with lymphoma

Campbell, Olivier; MacDonald, Valerie; Dickinson, Ryan; GAGNON, JEANNE

doi:10.1111/jsap.13080

Cited by 3 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thrombocytosis was observed in vincristine-treated patients with malignancies [37]. This phenomenon of increasing platelet counts was also observed in normal dogs or dogs with lymphoma with clinical vincristine treatment [12,18,20,38]. This ability of vincristine to increase platelet counts has led vincristine or vincristine-loaded platelets to be used to treat patients with ITP [11][12][13]15].…”

Section: Discussionmentioning

confidence: 90%

Influence of Vincristine, Clinically Used in Cancer Therapy and Immune Thrombocytopenia, on the Function of Human Platelets

Lien

Lin

et al. 2021

Molecules

View full text Add to dashboard Cite

Vincristine is a clinically used antimicrotubule drug for treating patients with lymphoma. Due to its property of increasing platelet counts, vincristine is also used to treat patients with immune thrombocytopenia. Moreover, antiplatelet agents were reported to be beneficial in thrombotic thrombocytopenic purpura (TTP). Therefore, we investigated the detailed mechanisms underlying the antiplatelet effect of vincristine. Our results revealed that vincristine inhibited platelet aggregation induced by collagen, but not by thrombin, arachidonic acid, and the thromboxane A2 analog U46619, suggesting that vincristine exerts higher inhibitory effects on collagen-mediated platelet aggregation. Vincristine also reduced collagen-mediated platelet granule release and calcium mobilization. In addition, vincristine inhibited glycoprotein VI (GPVI) signaling, including Syk, phospholipase Cγ2, protein kinase C, Akt, and mitogen-activated protein kinases. In addition, the in vitro PFA-100 assay revealed that vincristine did not prolong the closure time, and the in vivo study tail bleeding assay showed that vincristine did not prolong the tail bleeding time; both findings suggested that vincristine may not affect normal hemostasis. In conclusion, we demonstrated that vincristine exerts antiplatelet effects at least in part through the suppression of GPVI signaling. Moreover, this property of antiplatelet activity of vincristine may provide additional benefits in the treatment of TTP.

show abstract

Section: Discussionmentioning

confidence: 90%

Influence of Vincristine, Clinically Used in Cancer Therapy and Immune Thrombocytopenia, on the Function of Human Platelets

Lien

Lin

et al. 2021

Molecules

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…Most studies suggest that platelet function after vincristine administration is not impaired in healthy dogs, but 1 study found decreased platelet aggregation after vincristine in dogs with lymphoma. [31][32][33][34] Cats: a. There is insufficient evidence to determine with certainty if vincristine affects patient-centered outcomes in cats with pITP, but the limited evidence that is available suggests that vincristine may not be effective.…”

Section: Evidence Summarymentioning

confidence: 99%

ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats

LeVine,

Goggs,

Kohn

et al. 2024

Veterinary Internal Medicne

View full text Add to dashboard Cite

Management of immune thrombocytopenia (ITP) in dogs and cats is evolving, but there are no evidence‐based guidelines to assist clinicians with treatment decisions. Likewise, the overall goals for treatment of ITP have not been established. Immunosuppressive doses of glucocorticoids are the first line treatment, but optimal treatment regimens beyond glucocorticoids remain uncertain. Additional options include secondary immunosuppressive drugs such as azathioprine, modified cyclosporine, and mycophenolate mofetil, usually selected based on clinician preference. Vincristine, human IV immunoglobulin (hIVIg), and transfusion of platelet or red blood cell–containing products are often used in more severe cases. Splenectomy and thrombopoietin receptor agonists are usually reserved for refractory cases, but when and in which patient these modalities should be employed is under debate. To develop evidence‐based guidelines for individualized treatment of ITP patients, we asked 20 Population Intervention Comparison Outcome (PICO) format questions. These were addressed by 17 evidence evaluators using a literature pool of 288 articles identified by a structured search strategy. Evidence evaluators, using panel‐designed templates and data extraction tools, summarized evidence and created guideline recommendations. These were integrated by treatment domain chairs and then refined by iterative Delphi survey review to reach consensus on the final guidelines. In addition, 19 non‐PICO questions covering scenarios in which evidence was lacking or of low quality were answered by expert opinion using iterative Delphi surveys with panelist integration and refinement. Commentary was solicited from multiple relevant professional organizations before finalizing the consensus. The rigorous consensus process identified few comparative treatment studies, highlighting many areas of ITP treatment requiring additional studies. This statement is a companion manuscript to the ACVIM Consensus Statement on the Diagnosis of Immune Thrombocytopenia in Dogs and Cats.

show abstract

“…Moreover, given that thrombocytopenia is a common hematologic finding in dogs with lymphoma and leukemia, changes in platelet measurands in dogs with or without thrombocytopenia might provide useful information regarding diagnosis, prognosis, and possibly therapy. 6,24 The first objective of this study was to establish RIs for each of these measurands in a population of healthy dogs and evaluate whether differences exist when accounting for sex and age. The second objective was to compare platelet measurands from a healthy population of dogs with hematologic neoplasia and normal platelet counts.…”

Section: Introductionmentioning

confidence: 99%

“…There is no information regarding specific changes in the above‐mentioned platelet measurands in dogs with hematologic neoplasia compared with healthy dogs. Moreover, given that thrombocytopenia is a common hematologic finding in dogs with lymphoma and leukemia, changes in platelet measurands in dogs with or without thrombocytopenia might provide useful information regarding diagnosis, prognosis, and possibly therapy 6,24 …”

Section: Introductionmentioning

confidence: 99%

Investigation of platelet measurands in dogs with hematologic neoplasia

Phillips

Naskou

Spangler

2022

Veterinary Clinical Pathol

View full text Add to dashboard Cite

Introduction Thrombocytopenia has been associated with some neoplastic processes, including hematologic neoplasia. There is no information regarding specific changes in platelet measurands in dogs with hematologic neoplasia compared with healthy dogs. The objectives of our study were to establish RIs, evaluate platelet measurands in dogs with hematologic neoplasia, and compare these measurands in patients with hematologic malignancies with or without thrombocytopenia. Methods This was a retrospective study. Platelet measurands were determined using the ADVIA 120 Hematology analyzer when a CBC was performed and included the platelet count, MPV, platelet distribution width (PDW), plateletcrit (PCT), mean platelet component (MPC), platelet component distribution width (PCDW), mean platelet mass (MPM), platelet mass distribution width (PMDW), and number of large platelets. Reference intervals were determined retrospectively using data from 129 healthy dogs. Patients with hematologic neoplasia (n = 50) were identified through retrospective evaluation of medical records from the Auburn University Veterinary Teaching Hospital and separated into thrombocytopenic (n = 20) and nonthrombocytopenic groups (n = 30). Results Platelet count and PCT were significantly higher in older healthy dogs compared with younger dogs. Significant differences were identified when comparing healthy dogs with those with hematologic neoplasia without thrombocytopenia for PDW, PCDW, PMDW, and the number of large platelets, indicating the presence of more heterogeneous platelets. Thrombocytopenic dogs with hematologic neoplasia had significantly decreased MPCs and increased MPVs, MPMs, and PCDWs compared with nonthrombocytopenic dogs with neoplasia. Conclusions Dogs with hematologic neoplasia had more heterogeneous platelets, whereas thrombocytopenic patients with neoplasia had more activated platelets.

show abstract

Evaluation of the effect of vincristine on platelet count in dogs with lymphoma

Cited by 3 publications

References 15 publications

Influence of Vincristine, Clinically Used in Cancer Therapy and Immune Thrombocytopenia, on the Function of Human Platelets

Influence of Vincristine, Clinically Used in Cancer Therapy and Immune Thrombocytopenia, on the Function of Human Platelets

ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats

Investigation of platelet measurands in dogs with hematologic neoplasia

Contact Info

Product

Resources

About